Spinout Obseva Targets Preterm Labor Drug
By Marie Powers
Thursday, August 29, 2013
Merck Serono SA spinout Obseva SA hit the ground running with a CHF32 million (US$34.7 million) Series A financing led by Sofinnova Partners and co-led by Sofinnova Ventures and Novo A/S.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.